On April 13, 2026, Oragenics Inc. announced that the first patient has been dosed in its Phase IIa clinical trial in Australia for its lead candidate, ONP-002, aimed at treating concussion and mild traumatic brain injury (mTBI). This event is significant for the company as it progresses in its research and development efforts.